Prospective Study of Cysteamine in the Treatment of Melasma

• Autor(a) principal: Shibayama, Marília Dione Salvador
• Data de Publicação: 2019
• Outros Autores: Maranhão, Geraldo Neves de Albuquerque, Oliveira, Werbeston Douglas de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Cadernos de Prospecção (Online)
• DOI: 10.9771/cp.v12i5.32566
• Texto Completo: https://periodicos.ufba.br/index.php/nit/article/view/32566
• topic: Cisteamina; Melasma; Prospecção Tecnológica.; Cysteamine; Melasma; Technological Prospection.

The treatment of melasma, a pigmentary disorder characterized by dark patches on the skin, is difficult and time-consuming because there is no cure, only control. According to the latest studies in the field of dermatology, Cysteamine is an active agent that acts as a pigment broker, reducing the melanin of the skin, correcting melasma and hyperpigmentation of the skin. Cysteamine is a depigmentant, a bleaching agent with an antioxidant effect. Thus, this study aimed to conduct a survey of information on patents related to the use of Cysteamine as a skin depigmenter with melasma. It was used the patent Mapping, Bibliographic Survey and Discussion of literature . It was noticed that there is low production of articles published in Brazil, with foreign authors being the ones who publish the most on the subject researched. As in the international databases, the search result brought the different ways of using Cysteamine, not only in dermatology, but for capillary treatment, infections caused by fungi and viruses, diabetes, cystinosis, among others. However, specifically to treat melasma, there is still no record in Brazil.